Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-05-16
1999-08-31
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, 435 691, C07K 14715, A61K 3817, C12N 1512
Patent
active
059453974
ABSTRACT:
Human tumor necrosis factor receptor proteins having the of amino acids 1-235 are disclosed in SEQ ID NO:2. TNF receptor deletion variants having the sequence of amino acids 1-185 or 1-163 of SEQ ID NO:2 also display TNF bing activity. Murine TNF receptor proteins are also disclosed in SEQ ID NO:4 and are capable of binding TNF.
REFERENCES:
patent: 4675285 (1987-06-01), Clark et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5155027 (1993-10-01), Sledziewski et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5270038 (1993-12-01), Klimpel et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5712155 (1998-01-01), Smith et al.
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312: 724 (1984).
Gray et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," Nature 312: 721 (1984).
Baglioni et al., "Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition," J. Biol. Chem. 260:13395 (1985).
Aggarwall et al., "Characterization of receptors for human tumour necrosis factor and their regulation by .gamma.-interferon," Nature 318:665 (1985).
Yoshie et al., "Binding and Crosslinking of .sup.125 I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," J. Biochem. 100:531 (1986).
Israel et al., "Binding of Human TNF-.alpha. To High-Affinity Cell Surface Receptors: Effect of IFN," Immunology Letters 12:217 (1986).
Creasley et al., "A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity," Proc. Natl. Acad. Sci. USA 84:3293 (1987).
Stauber et al., "Human Tumor Necrosis Factor-.alpha. Receptor," J. Biol. Chem. 263:19098 (1988).
Aggarwal and Eessalu, "Induction of Receptors for Tumor Necrosis Factor-.alpha. by Interferons Is Not a Mojor Mechanism for Their Synergistic Cytotoxic Response," J. Biol. Chem. 262:10000 (1987).
Tsujimoto et al., "Interferon-.gamma. Enhances Expression of Cellular Receptors for Tumor Necrosis Factor," J. Immun. 136:2441 (1987).
Holtman and Wallach, "Down Regulation of the Receptors for Tumor Necrosis Factor by Interleukin 1 and 4.beta.-Phorbol-12-Myristate-13-Acetate," J. Immonol. 139:1161 (1987).
Shalaby et al., "Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor-Alpha," J. Leukocyte Biol. 41:196 (1987).
Unglaub et al, "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators," J. Exp. Med. 166:1788 (1987).
Yonehara et al., "A Cell-Killing Monoclonal Antibody (ANTI-Fas) To A Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor", J. Exp. Med. 169:1747 (1989).
Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids," Eur. J. Haematol. 41:414 (1988).
Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor .alpha.," J. Exp. Med. 167:1511 (1988).
Seckinger et al., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor .alpha. Inhibitor," J. Biol. Chem. 264:11966 (1989).
Engelmann et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," J. Biol. Chem. 264:11974 (1989).
Okayama and Berg, "High-Efficiency Cloning of Full-Length cDNA," Mol. Cell. Biol. 2:161 (1982).
Okayama and Berg, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," Mol. Cell. Biol. 3:280 (1983).
Aruffo and Seed, "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," Proc. Natl. Acad. Sci. USA 84:8573 (1987).
Yamasaki et al., Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN.beta. 2) Receptor, Science 241:825 (1988).
Sims et al., "cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily," Science 241:585 (1988).
Kull et al., "Cellular receptor for .sup.125 I-labelled tumor necrosis factor", PNAS 82:5756, 1985.
Tsujimoto et al., "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells", Arch. Biochem and Biophys. 563-568, 1986.
Suggs et al., "Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for human .beta..sub.2 -microglobulin", PNAS 78:6613, 1981.
Ashkenazi et al, Proc. Natl. Acad. Sci., USA, 88:10535-10539 (1991).
Capon et al, Nature, 337:525-530 (1989).
Evans et al, J. Exp. Med., 180:2173-2179 (1994).
Imamura et al, J. Immunol., 139:2989-2992 (1987).
Ishikura et al, Blood, 73:419-424 (1989).
Jones et al, Nature, 338:225-228 (1989).
Langer et al, In: New Advances on Cytokines, Eds. Romagnani et al, Raven Press, New York, pp. 349-354 (1992).
Lesslauer et al, Eur. J. Immunol., 21:2883-2886 (1991).
Loetscher et al, J. Biol. Chem., 266(2):18324-18329 (1991).
Mohler et al, J. Immunol., 151:1548-1561 (1993).
Peppel et al, J. Cell. Biochem. Supp., 0(15 Part F):118 (1991).
Peppel et al, J. Exp. Med., 174:1483-1489 (1991).
Rutka et al, Int. J. Cancer Res., 41:573-582 (1988).
Smith et al, J. Biol. Chem., 262:6951-6954 (1987).
Smith et al, Science, 248:1019-1023 (1990).
Dembic et al, Cytokine, 2:231-237 (1990).
Loetscher et al, Cell, 61:351-359 (1990).
Nophar et al, EMBO J., 9:3269-3278 (1990).
Loetscher, H., et al (1990) J. Biol. Chem. 265(33): 20131-38.
Hohmann, H.-P., et al. (1989) J. Biol. Chem. 264: 14927-34.
Smith, R.A., et al. (1989) J. Biol. Chem. 264: 14646-52.
Engelmann, H., et al. (1990). Two tumor necrosis factor-binding proteins purified from human urine. J. Biol. Chem. 265(3): 1531-36.
Kohno, T., et al. (1990). A second tumor necrosis factor receptor gene Sci. USA. 87(21): 8331-35.
Beckmann M. Patricia
Goodwin Raymond G.
Smith Craig A.
Fitzgerald David L.
Immunex Corporation
LandOfFree
Purified p75 (type II) tumor necrosis factor receptor polypeptid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified p75 (type II) tumor necrosis factor receptor polypeptid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified p75 (type II) tumor necrosis factor receptor polypeptid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426536